The development of Chimeric Antigen Receptor (CAR) T-cell therapy is a complex, multi-stage process demanding deep scientific expertise, specialized technologies, and rigorous quality control. Navigating this journey from target discovery to a clinical candidate involves significant time, resources, and risk.